NasdaqGM:ESPRPharmaceuticals
Esperion Therapeutics (ESPR) Turns Q4 Profit As Bears Question Trailing Losses And Balance Sheet
Esperion Therapeutics (ESPR) closed FY 2025 with fourth quarter revenue of US$168.4 million and basic EPS of US$0.26, alongside net income of US$61.8 million, marking a clean break from the losses seen earlier in the year. Over the past few quarters, the company has seen revenue move from US$51.6 million in Q3 2024 to US$64.9 million in Q1 2025, US$82.4 million in Q2, US$87.3 million in Q3 and then US$168.4 million in Q4. Basic EPS shifted from a loss of US$0.15 in Q3 2024 through losses of...